Astellas Pharma Inc (OTCPK:ALPMY)
$ 9.72 -0.18 (-1.82%) Market Cap: 17.43 Bil Enterprise Value: 21.25 Bil PE Ratio: 4,243.06 PB Ratio: 1.82 GF Score: 77/100

Astellas Pharma Inc R&D Meeting Transcript

Dec 07, 2021 / 06:30AM GMT
Release Date Price: $15.72 (+0.85%)
Naoki Okamura
Astellas Pharma Inc. - Executive VP, CFO, Chief Strategy Officer, Chief Business Officer & Representative Director

Now we'll start the presentation. Next slide, please. Good afternoon, everyone. This is Okamura. I'm quite sure that you are all busy, but thank you very much for your participation in this R&D meeting. In this October, our organization has changed. So today, we would like to introduce a new research organization structure.

Next slide, please. This is the caution statement for this meeting. Definitely, you already read about this. I would like to skip.

Next slide, please. Agenda for today. First, I will introduce the background of this reorganization and then Dr. Shitaka will explain the details.

Next slide, please. Next. In the CSP Corporate Strategy Plan 2021 that we announced in May this year, in order to show how Astellas will overcome the XTANDI patent cliff and achieve sustainable growth we presented mid- to long-term goals that extend beyond, 2027 when the patent expires, 2030. So as a result, we believe that our current vision for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot